Investors should monitor upcoming data readouts from the Phase 2 atopic dermatitis trial and the ongoing Phase 3 PTCL trial. The extended cash runway reduces near-term dilution risk and supports multiple value inflection points through 2027.
Price Chart
Executive Summary
Corvus Pharmaceuticals reported financial results for Q4 and full year 2025, highlighted by positive Phase 1 atopic dermatitis trial data for soquelitinib, initiation of a Phase 2 trial in the same indication, and a successful $189 million public offering extending cash runway into Q2 2028. Despite increased R&D spending and a slight YoY increase in net loss, the company is advancing multiple clinical programs with upcoming data catalysts.
Key Financial Metrics
Key Facts
- Positive Phase 1 data in atopic dermatitis: 75% of soquelitinib patients achieved EASI 75 vs. 20% placebo; no severe adverse events.
- Initiated Phase 2 atopic dermatitis trial with ~200 patients; additional Phase 2 trials in asthma and hidradenitis suppurativa planned for 2026.
- Completed public offering raising $189.4 million in net proceeds, extending cash runway into Q2 2028.
- Cash, cash equivalents, and marketable securities: $56.8 million as of December 31, 2025 (excluding $189.4 million from January 2026 financing).
- R&D expenses increased to $33.7 million in 2025 from $19.4 million in 2024 due to clinical and manufacturing costs.
- Net loss for 2025 was $15.3 million vs. $62.3 million in 2024, a significant improvement despite higher operating costs.
Financial Impact
The $189.4 million financing significantly strengthens the balance sheet and funds operations into 2028. R&D spend increased 74% YoY to $33.7 million, reflecting accelerated development.
Risk Factors
- Clinical trial results may not replicate Phase 1 success, particularly in larger, more diverse populations.
- The company remains pre-revenue with no near-term path to profitability; valuation is entirely dependent on clinical outcomes.
- Dilution from the recent offering may pressure shares in the short term despite long-term runway benefits.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255077 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | Institutional Cluster | $14.46 $12.42 | ▼ −14.11% | ▼ −13.58% | $10.90 (−24.62%) |
Jul 22, 2026 10w ago | 8-K | $13.68 $14.33 | ▲ +4.75% | ▲ +1.44% | $10.90 (−20.32%) |
Jun 11, 2026 16w ago | Institutional Cluster | $11.60 $16.20 | ▲ +39.66% | ▲ +37.76% | $10.90 (−6.03%) |
May 14, 2026 20w ago | 8-K | $13.66 $11.93 | ▼ −12.63% | ▼ −11.77% | $10.90 (−20.18%) |
May 7, 2026 21w ago | 8-K | $15.55 $11.12 | ▼ −28.49% | ▼ −28.51% | $10.90 (−29.90%) |
Apr 24, 2026 23w ago | DEFA14A | $15.92 $12.83 | ▼ −19.41% | ▼ −24.37% | $10.90 (−31.53%) |
Apr 21, 2026 23w ago | Press Release | $17.14 $12.21 | ▼ −28.76% | ▼ −33.68% | $10.90 (−36.41%) |
Mar 12, 2026 29w ago | Press Release | $15.32 $15.17 | ▼ −0.98% | ▼ −4.57% | $10.90 (−28.85%) |
Mar 5, 2026 30w ago | Press Release | $15.80 $14.71 | ▼ −6.87% | ▼ −4.82% | $10.90 (−30.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access